Floatz logo

FILGRASTIM

Gastrointestinal Stromal Tumor

Dana-Farber Cancer Instituteprotein_peptidePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Gastrointestinal Stromal Tumor cohort.

Asset / SponsorPhaseRating
Imatinib
M.D. Anderson Cancer Center
Phase 2BB
Cediranib
National Cancer Institute (NCI)
Phase 2BB
Ipilimumab
National Cancer Institute (NCI)
Phase 2B
Floxuridine
NYU Langone Health
Phase 2B
Octreotide Pamoate
Northwestern University
Phase 2B

View all 21 →

Same molecule, other indications

FILGRASTIM is also rated in:

plasma cell myelomaDormant
BBB
Indicative ·
79 / 100
View asset →
Burkitt lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →